Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.59 |
| ▸ | NPY4R | P50391 | 8/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.59 |
| ▸ | NPY1R | P25929 | 6/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30495683 | 0.90 | TFPI (0.62) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30495701 | 0.89 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RNMUR2 | |
| SCHEMBL30176416 | 0.88 | NPY2R (0.62) | NPY2RNPY4RNPY5RNPY1RNMUR2 | |
| SCHEMBL31295885 | 0.88 | NMUR2 (0.58) | NPY2RNPY4RNPY5RNPY1RNMUR2 | |
| SCHEMBL31295886 | 0.88 | NMUR2 (0.57) | NPY2RNPY4RNPY5RNPY1RNMUR2 | |
| SCHEMBL30495583 | 0.87 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RMAPK8 | |
| SCHEMBL31129148 | 0.86 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1ROPRD1 | |
| SCHEMBL31129135 | 0.86 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1ROPRD1 | |
| SCHEMBL29349981 | 0.86 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RNMUR2 | |
| SCHEMBL29679496 | 0.86 | CALCR (0.61) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20240050502-A1 | AMANITA MUSCARIA COMPOUNDS | CAAMTECH, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20230355701-A1 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | CAAMTECH, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4262775-A1 | AMANITA MUSCARIA COMPOUNDS | Caamtech, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220273620-A1 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | CAAMTECH, INC. | 2022-09-01 | — | — | US | disclosed |
| WO-2022132691-A1 | AMANITA MUSCARIA COMPOUNDS | CAAMTECH, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4003395-A1 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | Caamtech, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | NPY2R 26/4885NPY4R 66/4885NPY5R 48/4885 |
| US-20230355701-A1 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | HTR3A, HTR7, HTR5A | NPY2R 464/4885NPY4R 671/4885NPY5R 341/4885 |
| US-20220273620-A1 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS | HTR5A, DIMT1, GART | NPY2R 972/4885NPY4R 960/4885NPY5R 238/4885 |
| US-20240050502-A1 | AMANITA MUSCARIA COMPOUNDS | HTR3A, MANBA, MGAT2 | NPY2R 2082/4885NPY4R 2301/4885NPY5R 2096/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | NPY2R 114/4885NPY4R 338/4885NPY5R 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.